✦ LIBER ✦

Erlotinib in der Second-Line-Therapie nichtkleinzelliger Lungenkarzinome

✍ Scribed by M. Wolf

Publisher: Springer
Year: 2005
Tongue: German
Weight: 783 KB
Volume: 11
Category: Article
ISSN: 0947-8965
DOI: 10.1007/s00761-005-0942-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Second-line-Therapie der idiopathisch üb

Second-line-Therapie der idiopathisch überaktiven Blase

✍ B. Amend; D. Castro-Diaz; E. Chartier-Kastler; D. De Ridder; K. Everaert; M. Spi 📂 Article 📅 2009 🏛 Springer 🌐 German ⚖ 512 KB

Long-term second-line therapy in rheumat

Long-term second-line therapy in rheumatoid arthritis

✍ H. A. Bird 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 197 KB

Bevacizumab in der First-Line-Therapie d

Bevacizumab in der First-Line-Therapie des fortgeschrittenen NSCLC

✍ Norbert Hasenöhrl 📂 Article 📅 2007 🏛 Springer Vienna 🌐 German ⚖ 73 KB

Second-line treatments after first-line

Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer

✍ Jenn-Yu Wu; Jin-Yuan Shih; Chih-Hsin Yang; Kuan-Yu Chen; Chao-Chi Ho; Chong-Jen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 236 KB

## Abstract Gefitinib is effective as first‐line therapy for advanced nonsmall cell lung cancer (NSCLC). However, after failure of gefitinib, it is unknown whether any second‐line regimens could lead to better outcomes. To study the influence of different second‐line antitumor regimens on the outco

Second line therapy in rheumatoid arthri

Second line therapy in rheumatoid arthritis — A four year prospective study

✍ T. Pullar; J. A. Hunter; H. A. Capell 📂 Article 📅 1985 🏛 Springer 🌐 English ⚖ 531 KB

Cyclophosphamide as second-line therapy

Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks

✍ Luciano Rinaldi; P. Perini; M. Calabrese; P. Gallo 📂 Article 📅 2009 🏛 Springer Milan 🌐 English ⚖ 137 KB